Wednesday, 17 May, 2023 | 11:00 AM EST / 17:00 PM CEST | For APAC Region 17:00 PM JST
MEASURING DONOR-DERIVED CELL-FREE DNA IN YOUR LABORATORY USING HoloGRAFT
Cell-free DNA (cfDNA) has become the best-studied biomarker for graft injury. In this webinar, you will learn the state-of-the-art understanding of the role of donor-derived cfDNA in post-transplant monitoring of graft injury and its potential clinical utility. We shall review the different technologies available for relative and absolute quantification of dd-cfDNA, and how these technological choices impact laboratory workflow, turnaround time, analytical performance. We discuss how different biofluid sample sources may give different insight into graft injury. We shall introduce HoloGRAFT, Omixon's proprietary cell-free DNA assay and compare its measurement principle with other alternatives. We present the available clinical data to support the performance of the test in kidney transplantation. The session is followed by live Q&A.
“You will learn the state-of-the-art understanding of the role of donor-derived cfDNA in post-transplant monitoring.”
Attila Bérces, PhD
Founder & CEO, Omixon Biocomputing Ltd.
Monitoring absolute quantity of donor derived cfDNA
The HoloGRAFT™ Screening Plates, Monitoring Assays and HoloGRAFT™ Software meet the needs of any research application that requires highly sensitive detection and quantification of graft-derived, cell-free DNA after organ transplantation. HoloGRAFT uses copy number variant markers, stretches of DNA inherited in zero, one or two-copy forms.Read more
READY TO STEP INTO THE NEXT LEVEL
OF HLA SEQUENCING?
Contact your local Omixon representative at email@example.com and we will provide you all the necessary information.